Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-12-2000 | Paper Report

Chromosome 6 alterations

Author: Chris Jones

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

There is epidemiological evidence to suggest a precursor role for proliferative breast lesions and the subsequent development of breast carcinoma. The presence of genetic abnormalities in these lesions suggests a precursor role, and may shed light on the genetic alterations which may play a part in early breast tumorigenesis. Molecular studies investigating loss of heterozygosity (LOH) on a large series of putative precursor lesions strengthened the concept that hyperplasias may be precursor lesions of breast cancer. …
Literature
1.
Tibiletti MG, Sessa F, Bernasconi B, Cerutti R, Broggi B, Furlan D, Acquati F, Bianchi M, Russo A, Capella C, Taramelli R: A large 6q deletion is a common cytogenetic alteration in fibroadenomas, pre-malignant lesions. Clin Cancer Res. 2000, 6: 1422-1431.PubMed
Metadata
Title
Chromosome 6 alterations
Author
Chris Jones
Publication date
01-12-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2000-66709

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Paper Report

Membrane oestrogen receptor

Paper Report

Tamoxifen, angiogenesis, oestrogens and animal models

Paper Report

Enhanced activity of anti-Lewisyhumanised 3S193 when combined with Taxol

Paper Report

Normal mammary epithelial cells escape of senescence

Paper Report

HOXA5 regulation of p53 in breast tumours

Commentary

The mammary myoepithelial cell - Cinderella or ugly sister?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits